Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announces that it has expanded the license agreement for its Vaxiclase platform with the Serum Institute of India (SIIPL), the world’s largest vaccine manufacturer, to include the developed world in their addressable markets. The initial agreement, signed in 2015, covered emerging pharmaceutical markets.
More information on : https://www.genkyotex.com/images/PDF/FR/1_communique_de_presse/2018/Genkyotex_PR_Vaxiclase_SIIL_Expanded_Agreement_EN_vf.pdf